JZL 184

• CAT Number: I000418
• CAS Number: 1101854-58-3
• Molecular Formula: C27H24N2O9
• Molecular Weight: 520.51
• Purity: ≥95%
• Synonyms: 4-nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate
• Target: MAGL
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: 3 years -20C powder
• IC50: 8 nM [1]
• IUPAC Name: (4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
• InChI: InChI=1S/C27H24N2O9/c30-26(38-21-5-3-20(4-6-21)29(32)33)28-11-9-17(10-12-28)27(31,18-1-7-22-24(13-18)36-15-34-22)19-2-8-23-25(14-19)37-16-35-23/h1-8,13-14,17,31H,9-12,15-16H2
• InChIKey: SEGYOKHGGFKMCX-UHFFFAOYSA-N
• SMILES: C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]

JZL 184(CAT: I000418) is a potent and selective inhibitor of monoacylglycerol lipase (MAGL), widely used in neurobiology and cannabinoid research. With an IC50 of 8 nM for MAGL inhibition and 4 µM for fatty acid amide hydrolase (FAAH) in mouse brain membranes, it demonstrates remarkable specificity. By inhibiting MAGL, JZL 184 elevates 2-arachidonoylglycerol (2-AG) levels, facilitating the study of endocannabinoid signaling pathways involved in pain, inflammation, and neuroprotection. Its high potency and selectivity make it ideal for in vitro and in vivo applications, advancing therapeutic research on endocannabinoid system modulation and related disease interventions.